Physician

Victor M Aviles, MD

According to 2025 Medicare claims, Victor Aviles, MD (NPI: 1275501645) practices hematology/oncology in the Barnstable Town, MA market, with the plurality of this provider's patient population coming from Barnstable, MA. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1003677014; TIN: 223141761) and primary practice location at 02556-2820. Aviles is affiliated with the Mass General Brigham ACO, LLC (ACO ID: A4641), participating under the MSSP model.

Aviles' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 746 traditional Medicare patients, billed 279,860 HCPCS/CPT codes, and received $4,199,906 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 825 prescription claims across 143 beneficiaries totaling $4,058,296 in drug costs, led by Calquence (Acalabrutinib Maleate). DME data shows 75 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,277,522 to $4,199,906. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,744,313 to $4,058,296. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	917	257,387	$2,277,522
2016	783	237,991	$2,571,237
2017	782	251,954	$2,786,309
2018	847	287,084	$3,731,668
2019	802	326,035	$4,192,134
2020	787	320,511	$4,161,050
2021	787	332,261	$5,173,349
2022	728	290,107	$3,815,008
2023	724	274,310	$3,648,380
2024	746	279,860	$4,199,906

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	177	869	$1,744,313
2016	163	848	$1,993,076
2017	164	889	$1,974,410
2018	171	932	$2,842,789
2019	164	930	$3,690,135
2020	154	955	$3,739,850
2021	170	967	$3,312,377
2022	156	901	$4,384,414
2023	139	829	$3,423,457
2024	143	825	$4,058,296

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	31	$2,704
2016	N/R	59	$27,072
2017	N/R	14	$7,468
2018	N/R	N/R	N/R
2019	N/R	82	$8,520
2020	N/R	61	$6,118
2021	N/R	32	$2,149
2022	N/R	50	$1,790
2023	N/R	27	$8,453
2024	N/R	75	$1,980

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	350	877	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	440	840	$69
96372	Injection of drug or substance under skin or into muscle	149	748	$12
36415	Insertion of needle into vein for collection of blood sample	313	1,165	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	368	1,548	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	89	2,670	$1,020,083
Xtandi	Enzalutamide	35	1,050	$432,836
Revlimid	Lenalidomide	23	644	$408,501
Promacta	Eltrombopag Olamine	18	540	$382,719
Pomalyst	Pomalidomide	16	448	$358,881

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	37	$1,478
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	26	$276
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Victor M. Aviles, MD?

Tedicare shows public-source Medicare data for Victor M. Aviles, MD (NPI 1275501645), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Victor M. Aviles, MD have ACO affiliation data?

Victor M. Aviles, MD is shown with ACO affiliation data for Mass General Brigham ACO, LLC (MSSP, ACO ID A4641).

What billing organization is linked to Victor M. Aviles, MD?

Victor M. Aviles, MD is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1003677014) in the available physician profile data.

Does Victor M. Aviles, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.